10 mg Semaglutide Dosage Chart: Where This Dose Fits in the Schedule

The decision you're facing: licensed steps versus figures from unlicensed sources

Most people searching for a semaglutide 10 mg dosage chart have encountered it on a social-media post, a compounding pharmacy website, or a document that originated outside the UK's licensed supply chain. It is a reasonable thing to investigate. The answer, though, is clear: neither Wegovy (the injection) nor the oral Wegovy tablet uses a 10 mg step, and the MHRA has not approved any semaglutide product at that strength for weight management in the UK.

This matters for a practical reason. Compounded semaglutide, sometimes sold in multi-dose vials, is not subject to the same manufacturing controls, stability testing or concentration verification as a licensed pen or tablet. The MHRA has repeatedly warned that unlicensed weight-loss products sold online pose serious risks, including incorrect dosing and contamination. You can read a full overview of how licensed Wegovy works if you want the baseline before going further.

The decision, then, is not which row of a chart to follow. It is whether the product you are looking at is licensed in the UK at all, and whether it is being prescribed through a regulated route.

The licensed Wegovy injection dose ladder: what each step is for

A question our prescribers hear most weeks is whether the lower doses are worth taking at all, given that 2.4 mg (or 7.2 mg) is where the clinical evidence sits. The answer is that the earlier steps exist to give your digestive system time to adjust. Starting at 2.4 mg from week one would, for most people, produce significant nausea.

The NHS semaglutide medicines page sets out the injection schedule: 0.25 mg for the first four weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg as the standard maintenance dose, each step typically four weeks apart. The 7.2 mg dose, approved by the MHRA in January 2026 and available as a single-dose pen from April 2026, is for adults with a BMI of 30 or above and is titrated to by the prescriber after the standard steps. Titration pace is a clinical judgement. If tolerability is poor at a given step, a prescriber may pause the increase rather than push through it. A chart cannot make that call.

For a breakdown of how the full injection schedule is structured, including every concentration you may encounter, our 10 mg semaglutide dosage chart covers each rung in more detail.

The oral Wegovy tablet dose ladder: a separate schedule, not an extension of the injection

The Wegovy tablet, approved by the MHRA on 11 June 2026 as the UK's first licensed oral GLP-1 medicine for weight management, has its own four-step ladder: 1.5 mg, 4 mg, 9 mg and 25 mg, with a minimum of one month at each level. These numbers bear no direct relation to the injection's milligram figures because oral bioavailability of semaglutide is much lower than subcutaneous delivery; a 25 mg tablet produces a systemic effect broadly comparable to the 2.4 mg injection, not twenty-five times as much.

The tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, and nothing else, food or drink included, for at least thirty minutes afterwards. No refrigeration is needed, which makes it more convenient for travel and daily routine. People who are already established on the 2.4 mg weekly injection may move directly to the 25 mg tablet, but only following a clinical assessment. If you use a vial-based product and want to understand how your concentration translates to each scheduled step, our semaglutide 5 mg/ml dosage chart sets both schedules side by side if you want to compare them.

Why the dose is always your prescriber's decision, not a chart's

Licensed dose schedules exist because the clinical trials that generated weight-loss and safety data used those exact steps. The STEP 1 trial, which established the evidence base for Wegovy at 2.4 mg, enrolled participants on the standard titration; the results do not generalise to unlicensed concentrations or compressed timelines.

Adjusting a dose outside the licensed schedule, based on a chart from an unverified source, removes the safety net that the titration process provides. Signs that a dose increase is moving too fast include persistent nausea that does not ease within two weeks, vomiting that makes it difficult to stay hydrated, or any symptom severe enough to affect daily function. Those are signals to contact a prescriber, not to reduce the dose unilaterally. If you want to understand how each step maps to the full schedule before speaking to a clinician, our semaglutide dosage chart walks through what each licensed dose level involves, and our semaglutide dose chart covers exactly this situation alongside the guidance on whether to increase semaglutide after two weeks.

If you are deciding whether a licensed semaglutide treatment is right for you, and which form suits your circumstances, the free consultation at nume connects you with a GPhC-registered independent prescriber who reviews every application personally. Treatment decisions stay with the clinician, informed by your health history, not by what any chart says. Check your eligibility and start that conversation whenever you are ready.